Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Madrigal Pharmaceuticals (MDGL) Non-Current Assets (2019 - 2025)

Madrigal Pharmaceuticals (MDGL) has disclosed Non-Current Assets for 13 consecutive years, with $13.8 million as the latest value for Q4 2025.

  • Quarterly Non-Current Assets rose 48.27% to $13.8 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $50.3 million through Dec 2025, up 42.38% year-over-year, with the annual reading at $13.8 million for FY2025, 48.27% up from the prior year.
  • Non-Current Assets for Q4 2025 was $13.8 million at Madrigal Pharmaceuticals, down from $15.8 million in the prior quarter.
  • The five-year high for Non-Current Assets was $15.8 million in Q3 2025, with the low at $866000.0 in Q2 2023.
  • Average Non-Current Assets over 5 years is $5.3 million, with a median of $2.2 million recorded in 2021.
  • The sharpest move saw Non-Current Assets crashed 53.09% in 2023, then skyrocketed 830.83% in 2024.
  • Over 5 years, Non-Current Assets stood at $1.6 million in 2021, then dropped by 27.0% to $1.2 million in 2022, then soared by 171.49% to $3.3 million in 2023, then skyrocketed by 185.36% to $9.3 million in 2024, then skyrocketed by 48.27% to $13.8 million in 2025.
  • According to Business Quant data, Non-Current Assets over the past three periods came in at $13.8 million, $15.8 million, and $12.0 million for Q4 2025, Q3 2025, and Q2 2025 respectively.